Drug Trial Radar · NCT07917754
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
470
Planned (sponsor's estimate)
Start
Dec 13, 2026
Primary completion
Mar 13, 2037
Study completion Mar 13, 2037
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat relapsed or refractory, diffuse large B-cell lymphoma (R/R DLBCL). Relapsed means the cancer came back after treatment. Refractory means the number of cancer cells in the body did not go down or the cancer did not go away after treatment. Researchers want to learn if MK-1045, an immunotherapy, can treat R/R DLBCL when given with zilovertamab vedotin (ZV), a type of targeted therapy. The goals of this trial are to learn: * About the safety of MK-1045 and ZV and if participants tolerate them together. To tolerate these drugs together means that participants will receive the trial medicines unless they need to stop them due to health problems * About the number of participants whose cancer responds (gets smaller or goes away) to treatment with MK-1045 and ZV * If participants who receive MK-1045 and ZV live longer without the cancer growing or spreading compared to participants who receive standard treatments
Conditions
- Lymphoma, Large B-Cell, Diffuse
- Diffuse Large B-Cell Lymphoma
Interventions
MK-1045Biological
Intravenous (IV) administration
Zilovertamab vedotinBiological
1.5 or 1.75 mg/kg administered IV
RituximabBiological
375mg/m\^2, administered IV
Rituximab biosimilarBiological
375 mg/m\^2, administered IV
Polatuzumab vedotinBiological
1.8 mg/kg, administered IV
BendamustineDrug
90 mg/m\^2, administered IV for 2 consecutive days
LenalidomideBiological
25 mg, administered orally
TafasitamabBiological
12 mg/kg, administered IV, on Days 1, 4, 8, 15, and 22 for Cycle 1; Days 1, 8, 15, and 22 for Cycles 2 and 3; Days 1 and 15 for Cycles 4 to 12 (each Cycle is 28 days). After Cycle 12, administered once every 2 weeks
Rescue Medication - BiologicalBiological
Participants may receive Tocilizumab (or biosimilar) after administration of MK-1045 in the event of cytokine release syndrome
Rescue Medications - DrugDrug
Participants may receive the following rescue medications before administration of MK-1045: acetaminophen (or similar), diphenhydramine (or similar antihistamine), dexamethasone, Varicellazoster/herpes simplex virus prophylaxis (acyclovir, valacyclovir, famiciclovir), and pneumocystis jirovecii pneumonia prophylaxis (trimethoprim/sulfamethoxazole, dapsone, atovaquone, pentamidine).
Granulocyte-colony stimulating factor (G-CSF)Other
Given as prophylaxis as listed in the National comprehensive Cancer Network guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1A: Number of Participants Who Experience Dose Limiting Toxicity (DLT)Time frame: Up to approximately 42 days
- Part 1A and 1B: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 53 months
- Part 1A and 1B: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 11 months
- Part 1B: Objective Response Rate (ORR)Time frame: Up to approximately 53 months
- Part 2: Progression Free Survival (PFS)Time frame: Up to approximately 53 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.